Abatacept could delay rheumatoid arthritis for high-risk patients One year of treatment with biologic drug abatacept (Orencia; Bristol Myers Squibb) delays progression to rheumatoid arthritis (RA) for up to four years in high-risk patients, according to the results…

Study results suggest that one year of treatment with biologic drug #abatacept delays progression to #rheumatoidarthritis for up to four years in high-risk patients

#orencia #RA #arthritis #clinicalresearch #biologics

buff.ly/GP1eWdj